[TimAlerts] ATRS slowly moving up. nhod. $TEVA may want to aquire $MYL on Epipen Saga. https://consumerist.com/2016/11/10/mylan-to-start-selling-300-generic-epipen-pack-next-month/

[TimAlerts] $MYL I they interview the CEO yet?

[TimAlerts] Yes. more $MYL pressure is good for $ADMP - http://www.cnbc.com/2016/09/20/new-pressure-on-mylan-as-ceo-heather-bresch-prepares-to-testify.html

[TimAlerts] *NY AG LAUNCHES ANTITRUST INVESTIGATION INTO MYLAN ON EPIPEN $MYL @zbiotech

[TimChallenge] $ADMP might benefit from all the negative $MYL news today...

[TimAlerts] Adam Feuerstein @adamfeuerstein $MNKD inhaled epinephrine for anaphylaxis? Competition for $MYL EpiPen? Maybe not. Read:

[TimAlerts] $MNKD is "making progress" in developing a less costly alternative to $MYL

[TimAlerts] $MNKD is "making progress" in developing a less costly alternative to $MYL EpiPen.

[TimAlerts] $MNKD working on inhaler alternative to $MYL EpiPen

[TimChallenge] kinda seems similar/parallel in a sense with the Epi-pen stocks, $MYL is king, and kaboshed $ADMP, though $ADMP could still release news, but it will apparently take months before the FDA will even look/review their product again, since testing, and resubmitting takes as long...at least that is what I have heard...so in regards to $ADMP, I think that stock stays in its range of mid to high 2's with little volume...